ACOR

This post was just published on ZYX Short Sell Change Alert. On a fundamental basis, the prior target makes sense.  However since Acorda (ACOR) is a short term trade, trading is not about making sense but making money.  Technically oriented traders who do not always understand fundamentals are passing around buy signals on

These posts were published on ZYX Short Sell Change Alert. Consider taking profits on one-half of Acorda (ACOR) in the zone of $20 to $21.05.  Stop on the remaining is $21.55 to $22.36.   You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE

This post was just published on ZYX Short Sell Change Alert. ACOR is short from $48.73.  The stock was halted at $20.33, down $6.44.  The stock was being crushed before the halt as patents on Ampyra are invalidated.  ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking. We

It is time to take profits on Acorda Therapeutics (ACOR).   Consider  taking profits on the entire position of Acorda Therapeutics right here at $23.08. Ampyra, the drug that has caused most excitement  in Acora  Therapeutics, is not proving to be a very good drug as we had predicted.  

Subscribers to ZYX  Short Sell Change Alert took partial profits on Acorda  Therapeutics (ACOR)at $30.20 on Friday. We are holding partial position  for the prices to hit our target zone. This target zone was provided to the subscribers of  ZYX  Short Sell Change Alert at the time of the trade

Acorda Therapeutics (ACOR) is up due to the positive opinion on Marketing Authorization Application for its MS drug Ampyra in Europe.  This approval for Acorda Therapeutics was expected.  The big move in Acorda is unwarranted.  We are short selling in the strength now with an average price $32.98 and will add if the

We are lowering the stop on ACOR to $22.39 to protect profits.

As per the prior  post, now we are short on ACOR   from $30.98.